Silver prices plunged by a record 30% in a single session after President Trump nominated former Fed Governor Kevin Warsh to lead the central bank, a move seen as tempering expectations for aggressive rate cuts and bolstering the dollar.
ARK Invest's Cathie Wood made a significant $26 million investment in Broadcom stock last week, highlighting a strategic pivot towards AI infrastructure amid portfolio reshuffling. The move follows Broadcom's blockbuster earnings and comes as Wall Street maintains a bullish outlook on the chipmaker.
Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.
KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
U.S. stocks fell and precious metals plunged from record highs after President Trump nominated former Fed Governor Kevin Warsh to lead the central bank, sparking concerns over monetary policy direction and Fed independence.
Despite significant institutional purchases and regulatory progress, Bitcoin continues to drift lower, leading analysts and investors to question what price level will finally stem the tide.
U.S. equity markets slipped Thursday as Treasury yields climbed following President Trump's announcement that he will nominate former Fed Governor Kevin Warsh as the next central bank chair. The move, seen as potentially less dovish, overshadowed positive economic data and corporate earnings.
President Trump nominates Kevin Warsh, a former Fed governor with a history of advocating for lower interest rates and expressing favorable views on Bitcoin, to lead the Federal Reserve, a move that could reshape monetary policy and digital asset markets.
Bitcoin's sharp decline this week mirrors a wider market rout, with analysts pointing to a confluence of geopolitical tensions, policy fears, and tech sector volatility as key drivers. The sell-off raises fresh questions about near-term support levels for the flagship cryptocurrency.
Exxon Mobil and Chevron reported declines in full-year earnings as a sustained oil surplus pressured prices, though both companies highlighted strategic shifts toward LNG, chemicals, and power projects to fuel future growth.
With Bitcoin consolidating below $90,000, a significant retreat from its October highs, investors are weighing whether this is a strategic entry point or a warning sign. We examine the competing narratives shaping the market's next move.
President Donald Trump's selection of former Fed Governor Kevin Warsh to lead the central bank is being welcomed by analysts as a stabilizing choice, with immediate positive ripples across currency and precious metals markets.
Morgan Stanley reaffirms its Overweight rating on Nvidia with a $250 price target, citing the company's systemic advantage through its Vera Rubin platform and robust hyperscaler spending, despite acknowledging competitive and demand risks.
President Trump's nomination of Kevin Warsh, a known monetary policy hawk, to lead the Federal Reserve sent initial shockwaves through equities and bonds on Friday, raising questions about the future path of interest rates.
Twilio shares have faced significant pressure, dropping over 14% in the past month. As the cloud communications leader grapples with investor skepticism, analysts are divided on whether the sell-off presents a value entry point or reflects justified concerns about competition and margins.
A former investment advisor with ties to major Wall Street firms has been sentenced to six years behind bars for orchestrating a million-dollar fraud scheme, using client funds to finance a luxury lifestyle that included high-end cars and country club memberships.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
President Trump's nomination of former Fed governor Kevin Warsh to lead the central bank has sparked immediate concerns on Wall Street about political influence over monetary policy, setting the stage for a contentious Senate confirmation battle.
While major indices hold steady, a search for growth is turning the spotlight onto smaller companies. We examine three small-cap stocks—from insurance to banking to luxury watches—that are posting strong results and navigating unique challenges in the current market.
